Screening (genetic testing) for Breast and Ovarian Cancer Syndrome

Providence Portland Medical Center, Portland, OR
Targeting 6 different conditionsBiospecimen Collection +3 moreN/ARecruitingLed by Jackilen Shannon, Ph.D.Research Sponsored by OHSU Knight Cancer Institute

Study Summary

This trial offers free genetic testing to the public to learn the value of testing for high risk cancer types.

Eligible Conditions
  • Hereditary Breast and Ovarian Cancer Syndrome
  • Cancer
  • Blood Cancers
  • Breast Cancer
  • Lynch Syndrome
  • Neoplastic Syndromes

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
You are willing to provide a sample of your DNA.
The study is looking at a group of people who may or may not have a cancer diagnosis in their medical history.
You may or may not have cancer for cohort A.
You agree to provide a sample of your DNA.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adherence to standard of care for hereditary breast and ovarian cancer (HBOC) and Lynch syndromes
Cascade screening rate among Lynch or HBOC positive carriers
Effectiveness and sustainability of heritable cancer syndrome testing in the two novel testing populations
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Screening (genetic testing)Experimental Treatment4 Interventions
Patients undergo collection of saliva samples for genetic testing. If genetic test is positive, patients receive genetic counseling.
First Studied
Drug Approval Stage
How many patients have taken this drug
Biospecimen Collection
Completed Phase 1

Find a site

Who is running the clinical trial?

OHSU Knight Cancer InstituteLead Sponsor
220 Previous Clinical Trials
2,062,563 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,416 Previous Clinical Trials
41,211,655 Total Patients Enrolled
Oregon Health and Science UniversityOTHER
940 Previous Clinical Trials
6,804,085 Total Patients Enrolled

Media Library

Screening (genetic testing) Clinical Trial Eligibility Overview. Trial Name: NCT04494945 — N/A
Breast and Ovarian Cancer Syndrome Research Study Groups: Screening (genetic testing)
Breast and Ovarian Cancer Syndrome Clinical Trial 2023: Screening (genetic testing) Highlights & Side Effects. Trial Name: NCT04494945 — N/A
Screening (genetic testing) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04494945 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current total of participants in this experiment?

"Indeed, the information on indicates that recruitments are in progress for this trial which was initially posted by 3rd of September 2020 and lately modified on 15th of September 2022. The research requires 27500 participants from two distinct sites."

Answered by AI

Are there opportunities for patients to participate in this experiment at present?

"Correct. According to the website, this medical experiment is still actively recruiting patients who meet certain criteria; it was initially published on March 9th 2020 and has since been updated as recently as September 15th 2022. A total of 27,500 participants are needed at two different sites for the trial to be successful."

Answered by AI
~8730 spots leftby Jun 2025